Could be a merger of sorts, with Biotime controlling a % of ACTC. This would help each company considerably.
BR only has 4.5 MIL in OMED, and less in most other small stems. Biotime will be Cramer's 'Best of Breed' within a few years.
Assignee:CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA)US20110300111 - GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS
Amanda Mack, James Thomson: Methods for the production of ips cells using non-viral approach
Hyo Young Park, Eun Hyung Noh, Hyung-Min Chung, Man-Jong Kang, Eun Young Kim:
Efficient Generation of Virus-Free iPS Cells Using Liposomal Magnetofection
Keisuke Okita1, Masato Nakagawa1,2, Hong Hyenjong2, Tomoko Ichisaka1,3, Shinya Yamanaka1
Induced pluripotent stem (iPS) cells have been generated from mouse and human somatic cells by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog and Lin28 using retroviruses or lentiviruses. Patient-specific iPS cells could be useful in drug discovery and regenerative medicine. However, viral integration into the host genome increases the risk of tumorigenicity. Here, we report the generation of mouse iPS cells without viral vectors. Repeated transfection of two expression plasmids, one containing the complementary DNAs (cDNAs) of Oct3/4, Sox2, and Klf4 and the other containing the c-Myc cDNA, into mouse embryonic fibroblasts resulted in iPS cells without evidence of plasmid integration, which produced teratomas when transplanted into mice and contributed to adult chimeras. The production of virus-free iPS cells, albeit from embryonic fibroblasts, addresses a critical safety concern for potential use of iPS cells in regenerative medicine.
Apparently ISCO not the first to use a protein transcription to reprogram ips cells:
Cell-free production of transducible transcription factors for nuclear reprogramming
William C. Yang,1,‡ Kedar G. Patel,2,‡ Jieun Lee,3 Yohannes T. Ghebremariam,3 H. Edward Wong,2 John P. Cooke,3 and James R. Swartz1,2,*
"Ectopic expression of a defined set of transcription factors chosen from Oct3/4, Sox2, c-Myc, Klf4, Nanog, and Lin28 can directly reprogram somatic cells to pluripotency. These reprogrammed cells are referred to as induced pluripotent stem cells (iPSCs). To date, iPSCs have been successfully generated using lentiviruses, retroviruses, adenoviruses, plasmids, transposons, and recombinant proteins. Nucleic acid-based approaches raise concerns about genomic instability. In contrast, a protein-based approach for iPSC generation can avoid DNA integration concerns as well as provide greater control over the concentration, timing, and sequence of transcription factor stimulation. Researchers recently demonstrated that polyarginine peptide conjugation can deliver recombinant protein reprogramming factor (RF) cargoes into cells and reprogram somatic cells into iPSCs. However, the protein-based approach requires a significant amount of protein for the reprogramming process. Producing fusion reprogramming factors in the large amounts required for this approach using traditional heterologous in vivo production methods is difficult and cumbersome since toxicity, product aggregation, and proteolysis by endogenous proteases limit yields. In this work, we show that cell-free protein synthesis (CFPS) is a viable option for producing soluble and functional transducible transcription factors for nuclear reprogramming. ..."
Anyone gonna invest?
Asterias Biotherapeutics, Inc., a majority-owned subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it plans to file a registration statement with the Securities and Exchange Commission in November 2013 for an underwritten public offering of units, with each unit consisting of one share of Series B common stock, $0.0001 par value per share, and one redemption right in respect of one share of Series B common stock. The shares of Series B common stock and redemption rights will immediately separate after purchase and will be freely tradable as separate securities after the closing of the offering.
Asterias plans to use the net proceeds of the offering, expected to be between $12 million and $15 million, to fund its product development programs and for working capital. Asterias plans to apply to list the Series B common stock on the NYSE MKT under the symbol AST. Prices for the redemption rights are expected to be quoted on the OTC Bulletin Board. The number of units to be offered and the price range for the units have not yet been determined.
YES, 600+ patents, MOST in the world out of any one single company.
Looks like we have isolated 5 different adipose progenitor lines, very complex stuff. Much of the new info seems to be centered on producing regenerative therapies through these adipose cells including the regenerating islet cells for diabetes.
Any chance BTX will announce trials for their cancer/mammogram blood diagnostic test? I heard it was by years end, is that true? Maybe at the StemSummit?
Consideration to Geron and BioTime from Asterias; Distributions by Geron and Asterias
Under the terms of the Agreement, Geron has received from Asterias 6,537,779 shares of Asterias Series A common stock. Subject to applicable law, Geron will distribute these shares on a pro rata basis to Geron stockholders as promptly as practicable, other than with respect to fractional shares and with respect to stockholders residing in certain to-be-determined excluded jurisdictions, who will instead receive cash on a pro rata basis. As promptly as practicable following the distribution of the Asterias Series A common stock by Geron to its stockholders, Asterias will distribute the BioTime Warrants on a pro rata basis to the holders of Asterias Series A common stock.
Asterias will also pay to Geron royalties on the sale of products that are commercialized, if any, in reliance on Geron patents contributed or licensed to Asterias.
Asterias has issued to BioTime 21,773,340 shares of Asterias Series B common stock and 3-year warrants to purchase 3,150,000 additional shares of Asterias Series B common stock at an exercise price of $5.00 per share.
The Romulus Films, Ltd. Investment
In a related transaction, Asterias has obtained $5 million in equity financing pursuant to a Stock and Warrant Purchase Agreement with Romulus Films, Ltd., in exchange for 2,136,000 shares of Asterias Series B common stock, plus warrants to purchase approximately 350,000 additional shares of Asterias Series B common shares at an exercise price of $5.00 per share, with a three year term. Earlier this year, Romulus invested $5 million in BioTime, which BioTime used to fund the loan to Asterias for its operations.
Ownership of Asterias Terms of Asterias Series A and Series B Common Stock; Trading Markets
Upon the distributions of the Series A common stock to Geron’s stockholders described above, BioTime will own approximately 71.6%, Geron stockholders will own approximately 21.4%, and Romulus will own approxi
More good news on the way:
"We look forward to presenting the results of our SB-728-902 Cohort 5 and SB-728-1101 studies in December 2013, at the Sixth International Workshop on HIV Persistence, Reservoirs and Eradication Strategies."
This IP is key, double whammy when coupled with zincfinger. As far as i know we have a monopoly on this stuff.
Buying now might be a good idea. Positive HIV results are likely, even if affective in 80% of patients.
If so a partner will be announced immediately and this stock will skyrocket.
Nice job bashing Balt.
1) Biotime to announce over the next 12 months multiple regen, as well as cancer detection(PanCx) clinical trials in the US and EU. These will be revolutionary regenerative clinical trials never before seen in medical history.
2) By the end of 2013 have a CE mark for it's product ReneviaTM: